Table of Contents
Bone Marrow Research
Volume 2013, Article ID 565824, 7 pages
http://dx.doi.org/10.1155/2013/565824
Research Article

Validation of the EBMT Risk Score for South Brazilian Patients Submitted to Allogeneic Hematopoietic Stem Cell Transplantation

1Hematology and Bone Marrow Transplantation, Clinical Hospital of Porto Alegre, 90035-903 Porto Alegre, RS, Brazil
2Laboratory of Cell Culture and Molecular Analysis of Hematopoietic Cells, Clinical Hospital of Porto Alegre, 90035-903 Porto Alegre, RS, Brazil

Received 21 August 2013; Revised 4 November 2013; Accepted 6 November 2013

Academic Editor: Peter J. Quesenberry

Copyright © 2013 Beatriz Stela Pitombeira et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. Allogeneic hematopoietic stem cell transplantation (HSCT) is still associated with a high transplant-related mortality rate. In 2009, the EBMT risk score was validated as a simple tool to predict the outcome after allogeneic HSCT for acquired hematological disorders. Objectives. The aim of this study was to validate the applicability of the EBMT risk score for allogeneic HSCT on South Brazilian patients. Methods. A retrospective observational study was performed based on patients' records and data base at Hospital de Clínicas de Porto Alegre, including all allogeneic transplants for malignant and severe aplastic anemia from 1994 to 2010. Patients were categorized according to EBMT risk score and overall survival (OS). Nonrelapse mortality (NRM) and relapse rate (RR) were analyzed. Results. There were 278 evaluable patients. OS, NRM, and RR at five years median followup were 48.7%, 40.7%, and 30.7%, respectively. The OS was 81.8% for risk score 0 and 0% for score 6 ( ), and NRM was 13.6% and 80% for risk scores 0 and 6, respectively ( ). Conclusion. The EBMT risk score can be utilized as a tool for clinical decision making before allogeneic HSCT for malignant hematological diseases and severe aplastic anemia at a single center in Brazil.